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1108Lymphocyte Recovery Is a Major Determinant
of Outcome after Matched Unrelated Myeloablative
Transplantation for Myelogenous Malignancies
Katarina Le Blanc,1,2 A. John Barrett,3 Marie Schaffer, PhD.,1 Hans Ha¨gglund,2,4
Per Ljungman,2,4 Olle Ringden,1,5 Mats Remberger1A higher absolute lymphocyte count 1month (LC30) after allogeneic hematopoietic stem cell transplantation
(HSCT) is associated with better outcome in patients transplanted from a matched sibling. We studied 102
SCT patients with unrelated donor and matched unrelated donors and the relationship between LC30 and
outcome in patients with myelogenous leukemia. Conditioning was myeloablative using cyclophosphamide
(Cy) with busulfan (Bu; n5 61) or total body irradiation (TBI; n5 41). LC30 was low (\0.2 109/L) in
18 patients, intermediate (0.2-1.0 109L) in 67, and high (.1.0 109/L) in 17 patients. In multivariate anal-
ysis, independent factors associated with high relapse-free survival (RFS) were high LC30, high CD34 cell-
dose, and absence of acute graft-versus-host disease (aGVHD) grades II-IV. When analyzed as a continuous
variable in multivariate analysis, a higher LC30 was associated with a lower transplant-related mortality
(TRM; relative hazard [RH]5 0.87, P\.05), higher relapse-free survival (RH5 3.42, P5.036), and improved
survival (RH5 4.53, P5.016, excluding GVHD). In patients with high, intermediate, and low LC30, overall
survival (OS) was 91% versus 60%, versus 36% (P5.02 and .001, respectively). This significant relationship
was maintained in patients who did not develop GVHD by day 30. Significant risk factors to develop low
LC30 was chronic myelogenous leukemia (CML; hazard ratio [HR] 0.73, P5.001), prophylaxis with granu-
locyte colony-stimulating factor (G-CSF; HR 0.81, P5.02) and aGVHD (HR 0.84, P5.05). These results
indicate that LC30 is an independent prognostic factor for transplant outcome in matched unrelated SCT
for myelogenous malignancies.
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6/j.bbmt.2009.05.015lating lymphocytes from the donor attack residual
tumor cells in the early posttransplant phase and
thereby prevent relapse, but, at the same time, limit
success of the treatment by causing graft-versus-host
disease (GVHD). A slow recovery of the lymphocyte
count as a predictor of increased risk of relapse was first
proposed in patients treated with myeloablative (MA)
conditioning who received HLA-identical sibling
grafts as treatment for acute myelogenous leukemia
(AML) [1]. In subsequent studies, a low absolute lym-
phocyte count on day 30 (LC30) predicted worse out-
come after HLA-identical sibling transplants receiving
both T cell-depleted and unmanipulated grafts [2-7].
Natural killer (NK) cells, whichmediate cytotoxic-
ity without prior sensitization, are the first cells to
recover in the early posttransplant period [8-10].
Indeed, in haploidentical T cell-depleted transplants,
NK-killer cell immunoglobulin-like receptor (KIR)
incompatibility reduces the risk of relapse in myeloge-
nous but not lymphogenous malignancies [11]. Simi-
larly, NK cells as the dominant population in the
Table 1. Characteristics of Patients and Donors Included in
the Study Evaluating Lymphocyte Counts at day 30 after
HSCT
HSCTwith MUD N5 , or median (range)
N5 102
Diagnosis
AML 54
CML 38
MDS 10
Risk (low/high) 55/47
Age 37 (0-58)
Children (<18 years) 22 (22%)
Sex (M/F) 57/45
Donor age 36 (19-54)
Donor sex (M/F) 58/41
Female donor to Male recipient 12 (12%)
Stem cell source (BM/PBSC) 44/58
NC dose (108/kg) 7.6 (0.6-63.8)
CD34 dose (106/kg) 6.8 (0.2-56.4)
GVHD prophylaxis
CsA + MTX 97
Other 5
Conditioning:
TBI-based 41
Bu-based 61
G-CSF post-HSCT 63 (62%)
HSCT indicates hematopoietic stem cell transplantation; MUD, matched
Biol Blood Marrow Transplant 15:1108-1115, 2009 1109Lymphocyte Recovery after TransplantLC30 were recently found to improve transplant out-
come in chronic myelogenous leukemia (CML) and
AML, but not acute lymphoblastic leukemia (ALL)
[6,7].
Today, half of all stem cells transplants (SCTs) are
performed using grafts from matched unrelated
donors (MUD). Compared to HLA identical sibling
transplants, MUD transplants are associated with
a higher rate of transplant-related mortality (TRM).
The main reasons for this are higher frequencies of
rejection and acute GVHD (aGVHD) and an in-
creased incidence of infections because of prolonged
immunosuppression.
Taking advantage of the simplicity and reproduc-
ibility of the LC30 measurements as a surrogate for
NK cell recovery [6], we sought to determine whether
prompt lymphocyte recovery also predicted outcome
in MUD transplants. We retrospectively analyzed
the predictive role of LC30 in a cohort of 102 patients
undergoing MUD SCT after MA conditioning. The
results indicate that LC30 is a powerful predictor of
transplant outcome in myelogenous malignancies.unrelated donors; AML, acute myelogenous leukemia; CML, chronic
myelogenous leukemia; MDS, myelodysplastic syndrome; BM, bone mar-
row; PBSC, peripheral blood stem cells; NC, nucleated; CsA, cyclospor-
ine; GVHD, graft-versus-host disease; MTX, methotrexate; Bu, busulfan.MATERIAL AND METHODS
Patients
Onehundred twopatientswithmyelogenous leuke-
mia receiving MA conditioning and HSCT from
a HLA-A, -B, and -DR MUD were included in the
study. All patients were transplanted between October
1996 and January 2007, at the Karolinska University
Hospital, Stockholm, Sweden. A majority (53%) of
the patients had AML, whereas 38 had CML and 10
patients had myelodysplastic syndrome (MDS). The
median age was 37 years (range: 0.5-58 years). Patients
were considered low risk if they were in first complete
remission or chronic phase (CR1/CP1), whereas all
others were considered high risk. There were 55
(54%) low-risk and 47 high-risk patients. Patient and
donor demographics are displayed in Table 1. The
study was approved by the ethical committee and
performed in accordance with the declaration of
Helsinki.
Donors
There were 58 male and 41 female donors with
a median age of 36 years (19-54 years). For 3 trans-
plants, the sex of the donor was unknown. A female
donor to a male recipient was present in 12 cases.
HLA-typing
HLA class-II typing was performed using poly-
merase chain reaction (PCR) amplification with
sequence-specific primers (PCR-SSP) [12]. Before
1997, HLA class I-typing was performed by serologicmethods. Since 1997, we used PCR-SSP also for HLA
class I-typing, initially with low resolution and from
1999 with high resolution. All patients have recently
been retrospectively retyped using PCR-SSP with
allele level resolution for both HLA class I and II anti-
gens [13]. All patient and donor pairs were HLA-A, -B,
and -DR identical. However, an HLA-C mismatch
occurred in 32 cases (24 antigen mismatch and 8 allele
mismatch). Among the HLA-C mismatched pairs, 17
were KIR mismatched, 12 were KIR matched, and 3
were unknown.
Conditioning
All patients received conventionalMAconditioning
with cyclophosphamide (Cy; total dose 120 mg/kg) in
combination with busulfan (Bu; total dose 16 mg/kg)
(n5 61), 10 Gy single-dose total body irradiation
(TBI; n5 22), or 12 Gy fractionated TBI (n5 19)
[14]. All patients received anti-T cell antibodies during
conditioning [15]. Most patients received rabbit antith-
ymocyte globuline (ATG, Thymoglobulin n5 82,
Genzyme, Cambridge, MA), whereas 17 patients re-
ceived OKT-3 and 3 patients were given Campath
(Genzyme). The last dose of ATG was given on the
day before (day –1) graft infusion [14].
GVHD prophylaxis
GVHD prophylaxis consisted of cyclosporine
(CsA) in combination with 4 doses of methotrexate
1110 Biol Blood Marrow Transplant 15:1108-1115, 2009K. Le Blanc et al.(MTX; n5 97) [16,17], prednisolone (n5 3), or
mycophenolate mofetil [10] (MMF; n5 2). During
the first month, the blood CsA levels were kept at
200 to 300 ng/mL [18]. In the absence of GVHD,
CsA was discontinued after 6 months.
Stem-Cell Source
A bone marrow (BM) graft was given to 44 (43%)
patients, wheres 58 patients received peripheral blood
stem cells (PBSC) [19]. Nucleated (NC), CD341 and
CD31 cell doses are displayed in Table 1.
Supportive Care and Treatment of GVHD
Granulocyte colony-stimulating factor (G-CSF) was
given to 63 (62%) patients after HSCT until neutrophil
engraftment (.0.5 109/L) [20]. aGVHD and chronic
GVHD (cGVHD) was diagnosed on the basis of clinical
symptoms and/or biopsies (skin, liver, gastrointestinal
[GI] tract, or oral mucosa) according to standard criteria
and treated as previously described [21-23].
Definitions
Engraftment was defined as stable absolute neutro-
phil counts (ANC).0.5 109/L for 3 consecutive days
and platelet engraftment as platelet counts.50 109/
L for 7 consecutive days without transfusions.
Statistics
The analysis was performed in January 2008. The
probabilities of overall survival (OS) and relapse-free
survival (RFS) were estimated using the method devel-
oped by Kaplan-Meier and compared with the log-
rank test [24]. The incidence of GVHD, TRM, and re-
lapse was estimated nonparametrically. Patients were
censored at the time of death, relapse, or last follow-
up. Relapse and nonrelapse mortality (NRM) are com-
peting events. Their incidence rates were estimated us-
ing a nonparametric estimator of cumulative incidence
curves [25]. Predictive analyses for GVHD, TRM, and
relapse were based on the proportional hazard model
for subdistribution of competing risk. Univariate and
multivariate analyses were then performed using
Gray’s test and the proportional subdistribution haz-Table 2. Levels of Leukocytes, Lymphocytes, Absolute Neutroph
Depending on Diagnosis
AML CML
Leukocytes 5 (0.7-20.1) 3.7 (0.7-17
Lymphocytes 0.58 (0.05-2.8) 0.31 (0.09-1
ANC 3.0 (0.09-18.1) 2.8 (0.5-13
Hemoglobin 103 (71-140) 98 (69-133
Platelets 75 (7-374) 74 (8-324)
AML indicates acute myelogenous leukemia; CML, chronic myelogenous leuk
transplantation; ANC, absolute neutrophil count.
*P 5.01 versus AML.
†P < .001 versus AML.ard regression model developed by Fine and Gray
[26]. A stepwise backward procedure was used to
construct a set of independent predictors for each
endpoint. All predictors with a P-value below .10
were considered and sequentially removed if the P-
value in the multiple model was above .05. All tests
were 2 sided. The type I error rate was fixed at .05
for factors potentially associated with time-to-event
outcomes. Factors analyzed in the univariate analysis
include patient and donor sex and age, sex-mismatch,
diagnoses, disease stage, conditioning, GVHD pro-
phylaxis, stem cell source, G-CSF treatment, CMV se-
rology in patients and donors, nucleated and CD341
cell dose/kg, and GVHD. Analyses were performed
using the cmprsk package (developed by Gray, June
2001), Splus 6.2 software, and Statistica software.
The Mann-Whitney U test was used to compare
continuous variables, and the c2 method was used to
compare the distribution of categoric variables.RESULTS
Engraftment
Themedian time to neutrophil and platelet engraft-
ment was 16 (range: 10-32) and 17 (range: 9-210) days,
respectively. Platelet, hemoglobin, and neutrophil
counts on day 30 are shown inTable 2.The distribution
of theLC30 is shown inFigure1.ThemedianLC30was
0.48 (range: 0.05-2.8 109/L). We examined the im-
pact on transplant outcome of various cut-off points, in-
cluding the median lymphocyte count. The median
two-thirds (n5 67) with LC30 0.2-1.0 109/L showed
more homogeneous outcomes, whereas the outlying
third (LC30\0.2 109/L in 18 patients and
.1.0 109/L in the remaining 17) had the greatest dis-
parity in outcome.We therefore elected to analyze out-
comes according to 3 subgroups: low (0.2 109/L),
intermediate (0.2-1.0 109/L), and high (1.0 109/
L). Characteristics for patients with an LC30.
1.0 109/L were similar to those of the entire cohort.
When analyzed as continuous variables, the leukocyte
count correlated with ANC (r5 .97, P\ .001). Hemo-
globin values correlated with the leukocyte (r 5 .54,ils (ANC), Hemoglobin, and Platelets at Day 30 after HSCT
MDS All patients
.4)* 7.0 (0.6-16.4) 4.6 (0.6-20.1)
.7)† 0.58 (0.08-2.0) 0.48 (0.05-2.8)
.6) 4.9 (0.4-11.1) 2.9 (0.09-18.1)
) 92 (80-124) 100 (69-140)
81 (6-184) 75 (6-374)
emia; MDS, myelodysplastic syndrome; HSCT, hematopoietic stem cell
Figure 1. Distribution of absolute lymphocyte counts at day 30 after
unrelated donor HSCT. Figures are given as 109/L.
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as with the ANC (r5 .53, P\ .001). However, there
was no correlation between LC30 as a continuous vari-
able and the other values.
Relationship between LC30 and Cytokine Levels
Plasma levels of cytokines were measured in 15
subjects between days 12 and 32 posttransplant (total
21 samples). Six patients had a low (\0.2 109/L)
and 9 patients a high (.1.0 109/L) LC30. Plasma
IL-15 was lower in patients with high LC30 (median
32 pg/mL versus 56.5 pg/mL, P\ .05 log rank sum).
No significant difference in plasma level of IL-7
was seen between low and high LC30 (medianTable 3. Results from the Univariate Analysis of Factors Assoc
Unrelated Donor HSCT
Survival
RH 95% CI
LCC* 1.04 0.54-2.03
ALC* 0.35 0.15-0.85
ANC* 1.20 0.59-2.44
HB* 0.83 0.68-1.01
Platelet* 0.93 0.88-0.99
Patient age* 1.13 0.92-1.37
Donor age* 0.91 0.59-1.40
NC dose* 1.06 0.82-1.37
CD34 dose* 1.04 0.99-1.08
Low risk versus high risk 1.42 0.76-2.66
Acute leukemia versus all others 1.60 0.84-3.06
TBI versus Busulfan 0.88 0.47-1.64
aGVHD 0-1 versus aGVHD II-IV 3.90 2.04-7.44
FD to MR versus all other combinations 1.35 0.56-3.26
PBSC versus BM 1.39 0.73-2.66
cGVHD yes/no 1.05 0.50-2.21
G-CSF yes/no 1.95 0.93-4.12
LCC indicates day 30 leukocyte cell count; ALC, day 30 absolute lymphocyte
level; platelets, day 30 platelet count; NC dose, nucleated cell dose in graft (10
risk; >CR1/CP1; TBI, total body irradiation; aGVHD, acute graft-versus-host
PBSC, peripheral blood stem cells; cGVHD; chronic graft-versus-host disea
cyte-colony stimulating factor; RH, relative hazard.
*Analyzed as continuous variable.22.6 pg/mL for high LC30 versus 13.9 pg/mL for
low LC30, NS). IL-12 was detectable in only 1 patient
with low (\0.2 109/L) LC30 (median 0 pg/mL)
and in 5 of 9 patients (median 152 pg/mL) with high
(.1.0 109/L) LC30. IL-2 was detectable at levels
similar to an AB serum pool in only 1 patient with
low LC 30 and 1 patient with high LC30.
Factors Influencing Transplant Outcome
aGVHD
The cumulative incidence of aGVHDgrades II-IV
was 38% (95% confidence interval [CI] 29%-47%)
and that of grades III-IV GVHD was 12% (5%-
19%). The occurrence of aGVHD grades II-IV was
not affected by the donor type, patient age, stem cell
source, CD34 cell dose, or type of conditioning.
The only factor associated with a higher risk of
aGVHD grades II-IV in univariate analysis was a low
LC30, when analyzed as a continuous variable (relative
hazard [RH] 0.91, CI: 0.85-0.97, P5 0.01) (Table 3).
TRM
An increased risk of TRM was observed in univar-
iate analysis for patients with aGVHD II-IV (RH 13.2,
CI: 3.91-44.5, P\ .001). Analyzed as continuous vari-
ables, a low hemoglobin (0.72, 0.56-0.93, P5 .01) and
low LC30 (0.85, 0.76-0.96, P5 .005) were also associ-
ated with increased TRM. In multivariate analyses,
aGVHD grades II-IV, a low LC30, and G-CSF ad-
ministration postgraft were independently associated
with an increased risk of TRM (Table 4 andiated with Overall Survival and Relapse-Free Survival after
RFS
P-value RH 95% CI P-Value
.90 0.91 0.46-1.81 .78
.02 0.30 0.12-0.72 .007
.61 1.23 0.71-2.14 .46
.06 0.84 0.70-1.02 .08
.022 0.95 0.90-0.99 .04
.24 1.10 0.91-1.33 .34
.66 0.92 0.61-1.38 .68
.66 1.02 0.79-1.32 .87
.07 1.04 1.00-1.09 <.05
.28 1.30 0.71-2.38 .40
.15 1.43 0.78-2.63 .25
.68 0.86 0.47-01.58 .63
.00004 3.35 1.83-6.16 .0001
.50 1.19 0.50-2.81 .70
.32 1.22 0.67-2.24 .53
.89 0.90 0.44-1.87 .78
.08 2.05 1.01-4.16 <.05
count; ANC, day 30 absolute neutrophil count; HB, day 30 hemoglobin
8/kg), CD34, CD34+ cell dose in graft (106/kg); low risk, CR1/CP1; high
disease; FD to MR; female donor to male recipient; BM, bone marrow;
se; RFS, relapse-free survival; CI, confidence interval; G-CSF, granulo-
Table 4. Results from the Multivariate Analysis of Factors
Associated with Overall Survival (OS), Relapse-Free Survival
(RFS), Treatment-Related Mortality (TRM), and Graft-versus-
Host Disease (GVHD) after Unrelated Donor HSCT
Transplant-Related Mortality
RH 95% CI P-Value
aGVHD II-IV 12.3 3.63-41.7 <.001
LC30* 0.88 0.77-1.00 <.05
G-CSF 3.42 1.21-9.68 .02
Relapse-free survival
aGVHD II-IV 0.39 0.18-0.82 .014
LC30* 3.42 1.07-10.9 .036
CD34 dose* 0.95 0.91-0.99 .024
Overall survival
aGVHD II-IV 0.19 0.09-0.40 <.001
Platelets D +30* 1.10 1.04-1.17 .006
CD34 dose* 0.94 0.90-0.98 .002
LC30 indicates day 30 absolute lymphocyte count; platelets, day 30
platelet count; CD34 dose, CD34+ cell dose in graft (106/kg); aGVHD;
acute graft-versus-host disease; G-CSF; granulocyte-colony stimulating
factor administration postgraft; HSCT, hematopoietic stem cell trans-
plantation.
*Analyzed as continuous variables.
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ated with increased TRM if aGVHD was excluded
from the multivariate analysis (0.85, 0.76-0.96,
P5 .005).
RFS
The 5-year RFS for the entire cohort of patients
was 56%. Factors associated with a significantly
decreased RFS were aGVHD grades II-IV, low
LC30, and platelet counts (Table 3). Patients receiving
a low CD34 cell dose or G-CSF postgraft also had
lower RFS.Multivariate analysis showed that indepen-
dent factors associated with high RFSwere high LC30,
high CD34 cell dose, and absence of aGVHD grades
II-IV (Table 4). The probability of RFS is shown in
Figure 2b. The effect of LC 30 was examined for
counts of \0.2 109/L, 0.2-1 109/L, and .1.0
 109/L. Patients who had an LC30\0.2 109 were
at a significantly higher risk of treatment failure than
those with greater lymphocyte counts (2.53; 1.49-
4.31; P\ .001).
Survival factors
OS at 5 years for the entire cohort of patients was
61%. Factors identified as significant for inferior OS
in univariate analysis were a low CD34 cell dose, low
LC30 and platelet counts, and occurrence of aGVHD
grades II-IV (Table 3). In multivariate analysis, low
CD34 cell dose, low platelet count on day 30, and
aGVHD grades II-IV were independently correlated
with decreased survival (Table 4). When GVHD was
excluded from the multivariate analysis, a low CD34
cell dose (0.96, 0.92-0.99, P5 .026) and low LC30
(4.53, 1.32-15.5,P5 .016) remained as variables signif-icantly associated with decreased OS. Causes of death
in the low (\0.2 109/L) LC30 group were relapse
in 4 (22%), infection in 4 (22%), and GVHD in
3 (17%). In the intermediate LC30 group (0.2-
1.0 109/L), 12 (18%) patients died of relapse, 8
(12%) of infection, 5 (7%) of GVHD, and 2 of other
causes. In the group of patients with LC30.
1.0 109/L only 1 patient died (relapse).
LC30 Is an Independent Variable Influencing
Transplant Outcome
Because the LC30 correlated with aGVHD grades
II-IV, these patients were analyzed in more detail. Of
the 102 patients, 39 developed aGVHD grades II-IV.
In the 25 patients who developed $ grade II before
day 30, mean LC30 was 0.33 versus 0.58 in the 14 pa-
tients who developed$ grade II after day 30. Figure 2c
shows the cumulative incidence of grades II-IV
aGVHD in patients with different LC30. aGVHD
grades II-IV was significantly more common in pa-
tients with a low (\0.2 109/L) compared to
patients with a high (.1.0 109/L) LC30. Of the
patients with an LC30\0.2 109, 28% (5/18)
whereas none of the patients with LC30. 1.0 109
developed severe (grades III-IV) aGVHD (P5 .004).
Among patients with aGVHD grades II-IV, RFS
at 2 years was 22%, 40%, and 100% in patients
with LC30\0.2 109/L (n5 11), 0.2-1.0 109/L
(n5 25) and .1.0 109/L (n5 3). The correspond-
ing figures for patients with no or grade I aGVHD
were 43%, 67%, and 92%. To exclude the possibility
that occurrence of aGVHD or its treatment influenced
LC30, the RFS was recalculated, excluding 25 patients
who developed aGVHD before day 30. As shown in
Figure 2d, excluding aGVHD did not modify the
influence of lymphocyte count on RFS.
Risk Factors to Develop Low LC30
We did a risk-factor analysis to identify factors of
importance to develop a low LC30. The risk factors
included in univariate analysis in addition to those
listed in Materials and Methods were AB0 compatibil-
ity, Bu compared toTBI, thymoglobuline compared to
OKT-3, splenectomy, PBSCs compared to BM grafts.
In the univariate analysis, CML, aGVHD, and pro-
phylaxis using G-CSF to promote engraftment were
associated with a low LC30. The same factors were
also significant in the multivariate analysis (Table 5).DISCUSSION
There is accumulating data indicating that
lymphocyte recovery is a universal factor associated
with outcomes of hematologic malignancies after che-
motherapy, autologous BM transplantation, and allo-
geneic SCT between identical siblings [27]. Our
Figure 2. (a) Cumulative incidence of treatment-related mortality (TRM), (b) Actuarial relapse free survival (RFS) for all patients, (c) Cumulative
incidence of aGVHD grades II-IV of patients with an absolute lymphocyte count on day 130 (LC30)\0.2 109 (solid line), 0.2-1.0 109 (dotted
line) and $1.0 109 (dashed line). (d) Actuarial RFS for 77 patients who did not develop aGvHD before day 30.
Table 5. Results from the Multivariate Analysis of Factors
Associated with low LC30
RH 95% CI P-Value
CML 0.74 0.34-0.78 0.001
Prophylaxis with G-CSF 0.81 0.68-0.97 0.02
Acute GVHD II-IV (before day 30) 0.84 0.70-1.00 0.05
RH indicates relative hazard; CI, confidence interval; G-CSF, granulo-
cyte-colony stimulating factor; CML, chronic myelogenous leukemia;
LC30, day 30 absolute lymphocyte count.
Biol Blood Marrow Transplant 15:1108-1115, 2009 1113Lymphocyte Recovery after Transplantstudy, the first to specifically evaluate unrelated SCT,
concords with the general observation that higher lym-
phocyte counts favor better outcome, because of
a lower TRM, less relapse, and less GVHD, and ex-
tends this finding to the behavior of unrelated donor
lymphocytes recovering in transplant recipients of
HLA matched blood and marrow transplants. It could
be argued that aGVHD or its treatment with steroids
could have affected the lymphocyte count and that
the LC30 was only a surrogate for GVHD-related
events. In multivariate analysis both LC30 and
aGVHD were independent predictors of outcome.
However, when aGVHD was excluded from the mul-
tivariate analysis LC30 remained an independent vari-
able significantly associated with decreased OS.
Furthermore, when the RFS was recalculated, exclud-
ing 25 patients who developed aGVHD before day 30,
there was no difference in the significant impact of
LC30 on RFS.
The mechanism underlying a predictive effect of
lymphocyte recovery on outcome is not well defined.
It remains possible that LC30 is a surrogate for a lym-phocyte subset, and there is evidence from other stud-
ies that the LC30 correlated with recovery of NK cells
[6,7]. In this retrospective analysis, we did not measure
NK cells. Instead, we sought to relate lymphocyte
recovery with plasma cytokine levels in the early post-
transplant period. Only IL-15 was detectible at levels
elevated above the plasma control pool in all samples.
We found an inverse correlation between higher IL-15
levels (a growth factor forNK2 andCD81 T cells) and
LC30, consistent with negative feedback from a more
rapidNK cell recovery, limiting growth factor produc-
tion. Because early recovering NK cells are derived
1114 Biol Blood Marrow Transplant 15:1108-1115, 2009K. Le Blanc et al.from CD341 progenitors [6,7], the direct relationship
between LC30 and CD34 cell dose is also consistent
with a predominant NK recovery on day 30. To better
define the relationship of lymphocyte recovery with
specific lymphocyte subsets and cytokine patterns after
SCT more extensive studies will be needed.
Lymphocyte recovery appeared to be independent
of the presence or absence of donor-recipient KIR
mismatch, indicating that recovery of counts did not
relate to NK allogenicity per se. Our material did
not allow us to investigate whether a particular donor
KIR genotype correlates with high LC30 as reported
by Savani et al. [6,7]. However, consistent with that
study, the favorable effect of LC30 on relapse was
not seen in recipients with ALL transplanted in our
center (data not shown). Because ALL cells are less
susceptible to NK cytotoxicity than AML cells, this
further supports an NK cell-dependent mechanism
driving the outcome. Finally, it is possible that the
LC30 may simply be a surrogate for the quality of
engraftment. However, although the total leukocyte
count correlated with both neutrophil and platelet
counts as well as with the hemoglobin, no correlation
was found between the LC30 and the other variables.
Assuming that LC30 is in some way a biologically
relevant predictor of transplant outcome, the possibil-
ity of improving results of URD transplants by strate-
gies to increase lymphocyte recovery seems worth
exploring. NK cell recovery, for example, might be
improved by increasingCD34 count [6,7] (itself a pow-
erful predictor for outcome) [28]. Our data may sup-
port studies treating patients with BM boost,
mesenchymal stem cells, or evaluating the adoptive
transfer of donor NK cells (which do not increase
the risk of aGVHD) [29-31]. In addition, risk-adapted
strategies could be applied to recipients who failed to
achieve an LC30. 0.2 109/L, for example, selecting
such patients for preemptive donor lymphocyte infu-
sions (DLIs) to prevent relapse, intensifying GVHD
prophylaxis, and providing longer prophylactic cover-
age for opportunistic infections.
Finally, we did a risk-factor analysis for low LC30.
The most significant factor was CML. The reason for
this is unclear because patients with CML generally
have a good prognosis after autologous SCT (ASCT).
We have previously reported that G-CSF used to
promote engraftment was associated with an increased
risk of GVHD and death [32]. Some studies have
shown an increased mortality using G-CSF as prophy-
laxis after ASCT, although contradictory data also
exist [33]. Although G-CSF increases ANC, it causes
platelet aggregation and prolongs platelet engraftment
after ASCT [32]. It may therefore be possible that, al-
though it while promotes the production of ANC, it
adversely affects lymphocyte recovery [32]. That
GVHD decreases lymphocyte recovery is quite ex-
pected, because GVHD has both direct and indirecteffects on hematopoiesis by a graft-versus-hematopoi-
etic effect, and also by increasing the risk of infections
and toxic complications, leading to hemorrhages and
leukocyte consumption. All patients included in this
analysis were treated with ATG, OKT3, or Campath.
It is possible that treatment with anti-T cell antibodies
may delay lymphocyte recovery. However, because all
patients were treated equally, it does not explain differ-
ences noted between the different groups of patients
analyzed here. Lymphocyte recovery was also similar
in patients treated with either thymoglobulin or
OKT-3.
In conclusion, lymphocyte count early after SCT is
1 of the most universally measured reproducible and
powerful predictive factors for outcome. LC30 can
therefore readily be included as an outcome variable
in analyses of large multicenter databases to further
define its prognostic significance in different disease
and transplant types. Meanwhile, the predictive power
of the finding should stimulate further immunologic
laboratory studies to define the mechanism driving
lymphocyte recovery and NK cell recovery in particu-
lar, with a view to optimizing posttransplant outcome
by maximizing immune reconstitution after SCT.ACKNOWLEDGMENTS
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